

NIH EASTERN REGIONAL COMPREHENSIVE METABOLOMICS RESOURCE CORE

Promotion and Outreach Core

Application: Pilot and Feasibility Project

[Applicants must complete all Information Requested on Pages 1-3]

Title of Project:

Principal Investigator (PI) of the P&F Study:

Co-Investigator(s):

Organization(s):

P&F PI Address:

P&F PI Phone Number:

P&F PI Email Address:

ERCMRC Collaborating Investigators (funded by ERCMRC):

P&F Trainees (optional, funded by Applicant):

Budget for Metabolomics (up to \$50,000 in ERCMRC metabolomics analysis): \$_____

P&F PI Signature: _____

Date: _____

Submission: Submit the proposal electronically (via e-mail) as one PDF file to BOTH Susan Sumner (susan_sumner@unc.edu) and Susan McRitchie (susan_mcritchie@unc.edu) by 5 pm EST, March 16, 2017.

NIH EASTERN REGIONAL COMPREHENSIVE METABOLOMICS RESOURCE CORE

Promotion and Outreach Core

Application: Pilot and Feasibility Project

[Applicants must complete all Information Requested on Pages 1-3]

Proposal Instructions: Submit your proposal (MS Word, 1/2-inch margins, single-spaced, 11-point Arial type) containing each of the following sections:

The application deadline is March 16, 2017 at 5 pm. The following information is mandatory:

- Abstract
- Budget and budget justification
- NIH Biosketch for PI(s) and key personnel
- Research Proposal (5 page limit)
 - Specific Aims
 - Background
 - Significance and rationale for the use of metabolomics
 - Impact
 - Preliminary results (not required, but presentation of other available data for integration is desirable)
 - Experimental approach to derive samples to be analyzed by the ERCMRC
- Additional information to be provided (not included in the 5-page limit):
 - Future funding and plans for collaboration (e.g., RFA's, manuscripts)
 - P&F PI Eligibility Statement
 - Statement that the PI understands that the metabolomics data and the associated metadata must be uploaded to www.metabolomicsworkbench.org
 - References
 - Protection of Human Subjects/Animals in Research (include approval numbers for human subject research or use of animals in research; or indicate status of application)

The ERCMRC encourages applications that form scientific partnerships, span several scientific domains, includes trainees (paid by partnering laboratory), and benefits multiple investigators. The role of the PI, trainee(s), and the ERCMRC scientists should be clearly defined. The names of funded investigators will be posted on the ERCMRC website. Interested investigators should set-up a conference call to discuss the application with the PI/director or Program Coordinator at least 2 weeks in advance of the submission date.

**SEND APPLICATIONS TO BOTH THE ERCMRC PI AND PROGRAM COORDINATOR BY 5 PM EST on
MARCH 16th, 2017**

ERCMRC Director/PI - Dr. Susan Sumner, susan_sumner@unc.edu

ERCMRC Program Coordinator - Ms. Susan McRitchie, susan_mcritchie@unc.edu

SAMPLES MUST BE SUBMITTED TO THE ERCMRC WITHIN 2 MONTHS OF NOTIFICATION OF AWARD

NIH EASTERN REGIONAL COMPREHENSIVE METABOLOMICS RESOURCE CORE

Promotion and Outreach Core

Application: Pilot and Feasibility Project

[Applicants must complete all Information Requested on Pages 1-3]

Metabolomics Experience

1. Has the PI or Key Personnel been a (co)author on a manuscript or abstract using metabolomic strategies. Yes No (check one)

If yes, include citation

2. Is the PI or Key Personnel currently involved in a project that could result in a metabolomics manuscript or abstract: Yes No (check one)

3. Sample Suitability Questionnaire

- a. Are the proposed samples available now? Yes No
- i. Samples must be available within two months of the notification of award.
- b. For fluid samples (urine, serum, plasma, saliva etc.)
- i. What is the volume of sample available for the study? _____ ml
- ii. At what temperature have the samples been stored? _____
- iii. How many freeze/thaw cycles ? _____
- c. For Plasma: What anticoagulant was used?
- Heparin EDTA Citrate
- i. Were all samples processed with the same anticoagulant?
1. Yes No
- d. For tissue samples:
- i. What is the origin of the tissue (liver, brain, tumor, etc) _____
- ii. What mass of tissue is available for this study? _____ mg
- iii. Is the tissue proposed for metabotyping anatomically identical to that used for developing the phenotype? Yes No
1. If no, what are the differences.
- _____
- e. For Cells:
- i. What is the number of Cells available for analysis? _____
- ii. Do you determine total protein on your cells before shipment? _____